BiotechTube
Home/Cullinan Therapeutics/Gary Bridger
GB

Gary Bridger

Board Member

Cullinan Therapeutics

Therapeutic Areas

OncologyAutoimmune Diseases

Cullinan Therapeutics Pipeline

DrugIndicationPhase
CLN-978Systemic Lupus Erythematosus / Rheumatoid ArthritisPhase 1
Zipalertinib (CLN-081/TAS6417)EGFR Exon 20+ NSCLC (Relapsed/Refractory)NDA Submitted
CLN-049Relapsed/Refractory Acute Myeloid LeukemiaPhase 1
CLN-619Solid TumorsPhase 1
CLN-617Solid TumorsPhase 1

Leadership Team at Cullinan Therapeutics

NA
Nadim Ahmed
Chief Executive Officer
JR
Jeffrey R. Jones
Chief Medical Officer
TH
Thomas H. Held
Chief Operating Officer
JM
Jennifer Michaelson
Chief Development Officer
SV
Sylvie Vincent
Chief Business Officer
OH
Owen Hughes
Chief Financial Officer
OH
Owen Hughes
Executive Chairman of the Board
PB
Patrick Baeuerle
Scientific Co-Founder, Board Member
View full Cullinan Therapeutics profile